Boston Scientific Corporation $BSX Shares Sold by Triasima Portfolio Management inc.

Key Points

• Triasima sold 92.8% of its Boston Scientific stake in Q4, disposing of 45,169 shares and ending the period with 3,495 shares valued at $333,000.
• Institutional investors own 89.07% of BSX, with Vanguard notably increasing its position to 139,685,997 shares (about $13.32 billion), and other large managers like Invesco, Northern Trust, Amundi and Legal & General also adding to holdings.
• Boston Scientific slightly beat Q1 estimates with $0.80 EPS (vs. $0.79) and $5.20B revenue (up 11.6% YoY), and issued Q2 2026 guidance of $0.820–0.840 and FY2026 guidance of $3.340–3.410 EPS; consensus full-year EPS is ~3.38.

Triasima Portfolio Management inc. lowered its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 92.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 3,495 shares of the medical equipment provider's stock after selling 45,169 shares during the quarter. Triasima Portfolio Management inc.'s holdings in Boston Scientific were worth $333,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Boston Scientific by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider's stock valued at $13,319,060,000 after acquiring an additional 1,436,550 shares during the period. Invesco Ltd. grew its stake in Boston Scientific by 0.7% in the 3rd quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider's stock valued at $1,656,131,000 after acquiring an additional 111,826 shares during the period. Northern Trust Corp grew its stake in Boston Scientific by 0.9% in the 3rd quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider's stock valued at $1,406,129,000 after acquiring an additional 128,188 shares during the period. Amundi grew its stake in Boston Scientific by 17.5% in the 3rd quarter. Amundi now owns 11,981,584 shares of the medical equipment provider's stock valued at $1,158,619,000 after acquiring an additional 1,781,830 shares during the period. Finally, Legal & General Group Plc grew its stake in Boston Scientific by 4.6% in the 3rd quarter. Legal & General Group Plc now owns 10,457,175 shares of the medical equipment provider's stock valued at $1,020,934,000 after acquiring an additional 463,889 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Trading Up 0.8%

Shares of BSX stock opened at $56.96 on Tuesday. The stock's fifty day moving average is $67.06 and its two-hundred day moving average is $84.57. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The firm has a market capitalization of $84.66 billion, a P/E ratio of 23.83, a PEG ratio of 1.04 and a beta of 0.62. Boston Scientific Corporation has a fifty-two week low of $56.05 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts' consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.68% and a net margin of 17.29%.The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same quarter last year, the firm posted $0.75 EPS. The firm's revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts expect that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

BSX has been the topic of a number of research analyst reports. Robert W. Baird dropped their price target on shares of Boston Scientific from $86.00 to $78.00 and set an "outperform" rating on the stock in a research note on Thursday, April 23rd. UBS Group dropped their price target on shares of Boston Scientific from $120.00 to $105.00 and set a "buy" rating on the stock in a research note on Tuesday, March 17th. Needham & Company LLC decreased their price objective on Boston Scientific from $97.00 to $77.00 and set a "buy" rating on the stock in a report on Thursday, April 23rd. National Bank Financial set a $115.00 price objective on Boston Scientific in a report on Monday, February 2nd. Finally, Wall Street Zen lowered Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, March 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $93.91.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.